8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Mar 25, 2026·SEC
Material company update
Feb 24, 2026·SEC
Corcept Therapeutics Incorporated(CORT)Earnings, Financials & Key Ratios
CORT•NASDAQ
97.5× P/E·Price updated Jun 19, 2026
AboutCorcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.Show more
- Revenue$761M+12.8%
- EBITDA$47M-66.2%
- Net Income$100M-28.7%
- EPS (Diluted)0.82-33.3%
- Gross Margin98.3%
- EBITDA Margin6.13%-70.1%
- Operating Margin5.88%-71.0%
- Net Margin13.09%-36.8%
- ROE15.01%-36.3%
CORT Key Insights
Corcept Therapeutics Incorporated (CORT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓FCF machine: 18.6% free cash flow margin
- ✓Momentum leader: RS Rating 91 (top 9%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 16.6%
- ✓Good 3Y average ROE of 19.9%
✗Weaknesses
- ✗Expensive at 14.8x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CORT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CORT Price & Volume
Corcept Therapeutics Incorporated (CORT) stock price & volume — 10-year historical chart
Loading chart...
CORT Growth Metrics
Corcept Therapeutics Incorporated (CORT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years31.23%
5 Years16.56%
3 Years23.74%
TTM12.2%
Profit CAGR
10 Years-
5 Years-1.23%
3 Years-0.58%
TTM-64.01%
EPS CAGR
10 Years-
5 Years-0.72%
3 Years-1.95%
TTM-69.83%
Return on Capital
10 Years27.78%
5 Years20.59%
3 Years16.64%
Last Year6.54%
CORT Recent Earnings
Corcept Therapeutics Incorporated (CORT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$0.30-111.3%
$0.14
Rev
$165M-11.0%
$185M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$0.20-39.4%
$0.33
Rev
$202M-20.7%
$255M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.16-11.1%
$0.18
Rev
$208M-18.7%
$255M
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$0.29+26.1%
$0.23
Rev
$194M-20.5%
$245M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.30vs $0.14-111.3% | $165Mvs $185M-11.0% |
| Q1 2026 | Feb 24, 2026 | $0.20vs $0.33-39.4% | $202Mvs $255M-20.7% |
| Q4 2025 | Nov 4, 2025 | $0.16vs $0.18-11.1% | $208Mvs $255M-18.7% |
| Q3 2025 | Jul 31, 2025 | $0.29vs $0.23+26.1% | $194Mvs $245M-20.5% |
Based on last 12 quarters of dataView full earnings history →
CORT Peer Comparison
Corcept Therapeutics Incorporated (CORT) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 HRMY | 1.93B | 33.28 | 12.28 | 21.51% | 16.2% | 17.19% | 0.28 | |
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 PAHC | 1.29B | 31.85 | 26.76 | 27.37% | 6.29% | 30.81% | 2.67 | |
 VNDA | 342.83M | 5.80 | -1.55 | 8.72% | -109.99% | -61.41% | 0.04 | |
 OSUR | 305.85M | 4.25 | -4.52 | -38.1% | -61.93% | -15.09% | 0.04 | |
 AXSM | 12.89B | 250.50 | -68.07 | 65.55% | -26.59% | -260.01% | 2.73 |
Compare CORT vs Peers
Corcept Therapeutics Incorporated (CORT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CORT Income Statement
Corcept Therapeutics Incorporated (CORT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 159.2M | 251.25M | 306.49M | 353.87M | 365.98M | 401.86M | 482.38M | 675.04M | 761.41M | 769.1M |
Revenue Growth % | 95.77% | 57.82% | 21.99% | 15.46% | 3.42% | 9.8% | 20.04% | 39.94% | 12.79% | 12.2% |
Cost of Goods Sold | 3.55M | 5.21M | 5.5M | 5.58M | 5.28M | 5.38M | 6.48M | 10.88M | 12.98M | 13.46M |
COGS % of Revenue | 2.23% | 2.08% | 1.8% | 1.58% | 1.44% | 1.34% | 1.34% | 1.61% | 1.7% | - |
Gross Profit | 155.65M▲ 0% | 246.03M▲ 58.1% | 300.98M▲ 22.3% | 348.29M▲ 15.7% | 360.7M▲ 3.6% | 396.47M▲ 9.9% | 475.89M▲ 20.0% | 664.16M▲ 39.6% | 748.43M▲ 12.7% | 755.64M▲ 0% |
Gross Margin % | 97.77% | 97.92% | 98.2% | 98.42% | 98.56% | 98.66% | 98.66% | 98.39% | 98.3% | 98.25% |
Gross Profit Growth % | 96.37% | 58.07% | 22.33% | 15.72% | 3.56% | 9.92% | 20.03% | 39.56% | 12.69% | - |
Operating Expenses | 102.79M | 156.54M | 189.38M | 220.09M | 236.22M | 283.84M | 368.61M | 527.21M | 703.63M | 763.86M |
OpEx % of Revenue | 64.57% | 62.3% | 61.79% | 62.19% | 64.54% | 70.63% | 76.42% | 78.1% | 92.41% | - |
Selling, General & Admin | 62.42M | 81.29M | 100.36M | 105.33M | 122.36M | 152.85M | 184.26M | 280.32M | 448.73M | 503.42M |
SG&A % of Revenue | 39.21% | 32.35% | 32.75% | 29.76% | 33.43% | 38.04% | 38.2% | 41.53% | 58.93% | - |
Research & Development | 40.38M | 75.25M | 89.02M | 114.76M | 113.86M | 130.99M | 184.35M | 246.89M | 254.91M | 260.44M |
R&D % of Revenue | 25.36% | 29.95% | 29.04% | 32.43% | 31.11% | 32.6% | 38.22% | 36.57% | 33.48% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Operating Income | 52.85M▲ 0% | 89.5M▲ 69.3% | 111.61M▲ 24.7% | 128.2M▲ 14.9% | 124.48M▼ 2.9% | 112.63M▼ 9.5% | 107.28M▼ 4.8% | 136.95M▲ 27.7% | 44.8M▼ 67.3% | -8.22M▲ 0% |
Operating Margin % | 33.2% | 35.62% | 36.41% | 36.23% | 34.01% | 28.03% | 22.24% | 20.29% | 5.88% | -1.07% |
Operating Income Growth % | 419.26% | 69.32% | 24.7% | 14.87% | -2.91% | -9.51% | -4.75% | 27.66% | -67.29% | - |
EBITDA | 52.96M | 89.73M | 113.78M | 130.44M | 127.54M | 113.89M | 108.32M | 138.29M | 46.69M | -6.79M |
EBITDA Margin % | 33.27% | 35.71% | 37.12% | 36.86% | 34.85% | 28.34% | 22.46% | 20.49% | 6.13% | -0.88% |
EBITDA Growth % | 415.89% | 69.43% | 26.8% | 14.64% | -2.22% | -10.7% | -4.89% | 27.66% | -66.24% | -106.03% |
D&A (Non-Cash Add-back) | 106K | 236K | 2.17M | 2.24M | 3.07M | 1.26M | 1.04M | 1.34M | 1.89M | 1.43M |
EBIT | 52.85M | 89.5M | 111.61M | 128.2M | 125.01M | 112.63M | 107.28M | 136.95M | 44.8M | -8.22M |
Net Interest Income | -49K | 2.66M | 5.07M | 3.4M | 529K | 3.56M | 17.27M | 24.54M | 0 | 0 |
Interest Income | 0 | 2.66M | 5.07M | 3.4M | 529K | 3.56M | 17.27M | 24.54M | 0 | 0 |
Interest Expense | 49K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -49K | 2.66M | 5.07M | 3.4M | 529K | 3.56M | 17.27M | 24.54M | 21.67M | 20.35M |
Pretax Income | 52.81M▲ 0% | 92.15M▲ 74.5% | 116.68M▲ 26.6% | 131.6M▲ 12.8% | 125.01M▼ 5.0% | 116.19M▼ 7.1% | 124.56M▲ 7.2% | 161.49M▲ 29.7% | 66.46M▼ 58.8% | 12.13M▲ 0% |
Pretax Margin % | 33.17% | 36.68% | 38.07% | 37.19% | 34.16% | 28.91% | 25.82% | 23.92% | 8.73% | 1.58% |
Income Tax | -76.32M | 16.74M | 22.5M | 25.59M | 12.49M | 14.77M | 18.42M | 20.28M | -33.19M | -35.77M |
Effective Tax Rate % | -144.52% | 18.17% | 19.28% | 19.45% | 9.99% | 12.71% | 14.79% | 12.56% | -49.94% | -294.91% |
Net Income | 129.12M▲ 0% | 75.41M▼ 41.6% | 94.18M▲ 24.9% | 106.01M▲ 12.6% | 112.51M▲ 6.1% | 101.42M▼ 9.9% | 106.14M▲ 4.7% | 139.73M▲ 31.6% | 99.65M▼ 28.7% | 47.9M▲ 0% |
Net Margin % | 81.11% | 30.01% | 30.73% | 29.96% | 30.74% | 25.24% | 22% | 20.7% | 13.09% | 6.23% |
Net Income Growth % | 1486.27% | -41.6% | 24.89% | 12.56% | 6.13% | -9.86% | 4.66% | 31.65% | -28.68% | -64.01% |
Net Income (Continuing) | 129.12M | 75.41M | 94.18M | 106.01M | 112.51M | 101.42M | 106.14M | 141.21M | 99.65M | 47.9M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 1.04▲ 0% | 0.60▼ 42.3% | 0.77▲ 28.3% | 0.85▲ 10.4% | 0.89▲ 4.7% | 0.87▼ 2.2% | 0.94▲ 8.0% | 1.23▲ 30.9% | 0.82▼ 33.3% | 0.46▲ 0% |
EPS Growth % | 1385.71% | -42.31% | 28.33% | 10.39% | 4.71% | -2.25% | 8.05% | 30.85% | -33.33% | -69.83% |
EPS (Basic) | 1.14 | 0.60 | 0.82 | 0.92 | 0.97 | 0.95 | 1.02 | 1.35 | 0.95 | - |
Diluted Shares Outstanding | 124.52M | 126.69M | 122.57M | 124.19M | 125.96M | 115.97M | 111.74M | 113.48M | 119.99M | 104.44M |
Basic Shares Outstanding | 113.53M | 125.68M | 114.35M | 115.41M | 115.65M | 106.79M | 103.56M | 103.23M | 103.86M | 104.44M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CORT Balance Sheet
Corcept Therapeutics Incorporated (CORT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 140.6M | 240.59M | 307.36M | 478.5M | 266.46M | 499.25M | 458.64M | 471.6M | 485.46M | 426.03M |
Cash & Short-Term Investments | 104.03M | 206.76M | 275.96M | 440.7M | 223.53M | 431.67M | 368.22M | 383.33M | 372.15M | 338.18M |
Cash Only | 104.03M | 206.76M | 31.27M | 76.19M | 77.62M | 66.33M | 135.55M | 127.67M | 120.5M | 108.74M |
Short-Term Investments | 0 | 0 | 244.69M | 364.51M | 145.92M | 365.34M | 232.67M | 255.67M | 251.66M | 229.45M |
Accounts Receivable | 28.2M | 17.59M | 19.93M | 26.2M | 29.02M | 46.86M | 56.82M | 58.08M | 59.79M | 39.07M |
Days Sales Outstanding | 64.64 | 25.55 | 23.73 | 27.02 | 28.95 | 42.56 | 43 | 31.4 | 28.66 | 28.6 |
Inventory | 8.38M | 16.24M | 5.42M | 4.91M | 4.99M | 6.1M | 7.73M | 12.41M | 12.87M | 12.89M |
Days Inventory Outstanding | 860.23 | 1.14K | 359.69 | 321.06 | 344.75 | 413.46 | 435.34 | 416.32 | 361.93 | 341.64 |
Other Current Assets | 2.67M | 7.74M | 6.04M | 6.7M | 8.91M | 14.62M | 25.86M | 8.29M | 40.66M | 35.89M |
Total Non-Current Assets | 79.94M | 71.1M | 104.95M | 93.23M | 157.29M | 84.18M | 162.88M | 368.95M | 351.19M | 388.85M |
Property, Plant & Equipment | 518K | 655K | 4.5M | 4.18M | 1.52M | 1.78M | 315K | 8.01M | 6.47M | 10.37M |
Fixed Asset Turnover | 307.34x | 383.58x | 68.17x | 84.58x | 241.41x | 226.27x | 1531.35x | 84.24x | 117.63x | 99.17x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 15.28M | 0 | 39.35M | 36.2M | 112.28M | 4.95M | 57.18M | 219.83M | 0 | 275.33M |
Other Non-Current Assets | 3.24M | 7.79M | 15.43M | 21.25M | 16.05M | 15.99M | 14.79M | 10.19M | 176.52M | 196.92M |
Total Assets | 220.54M▲ 0% | 311.69M▲ 41.3% | 412.31M▲ 32.3% | 571.73M▲ 38.7% | 423.76M▼ 25.9% | 583.43M▲ 37.7% | 621.52M▲ 6.5% | 840.55M▲ 35.2% | 836.65M▼ 0.5% | 814.88M▲ 0% |
Asset Turnover | 0.72x | 0.81x | 0.74x | 0.62x | 0.86x | 0.69x | 0.78x | 0.80x | 0.91x | 0.94x |
Asset Growth % | 220.77% | 41.33% | 32.28% | 38.66% | -25.88% | 37.68% | 6.53% | 35.24% | -0.46% | 13.02% |
Total Current Liabilities | 29.57M | 35.81M | 38.84M | 47.49M | 47.54M | 72.49M | 104.5M | 140.77M | 166.09M | 149.19M |
Accounts Payable | 8.58M | 8.27M | 7.54M | 10.55M | 6.91M | 11.98M | 17.4M | 15.38M | 40.44M | 33.31M |
Days Payables Outstanding | 881.07 | 578.54 | 499.82 | 690.11 | 477.45 | 811.74 | 979.72 | 515.74 | 1.14K | 893.18 |
Short-Term Debt | 0 | 0 | 1.56M | 2.05M | 526K | 1.14M | 151K | 829K | 1.08M | 1.63M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 12.42M | 17.89M | 16.94M | 24.75M | 26.25M | 43.77M | 59.69M | 82.65M | 124.56M | 114.25M |
Current Ratio | 4.75x | 6.72x | 7.91x | 10.07x | 5.60x | 6.89x | 4.39x | 3.35x | 2.92x | 2.86x |
Quick Ratio | 4.47x | 6.26x | 7.77x | 9.97x | 5.50x | 6.80x | 4.31x | 3.26x | 2.85x | 2.77x |
Cash Conversion Cycle | 43.8 | 583.79 | -116.39 | -342.03 | -103.75 | -355.72 | -501.38 | -68.02 | -746.96 | -522.94 |
Total Non-Current Liabilities | 0 | 239K | 2.29M | 899K | 409K | 9.1M | 10.31M | 20.19M | 22.76M | 27.71M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.02M | 8.01M |
Capital Lease Obligations | 0 | 0 | 1.9M | 501K | 0 | 0 | 0 | 6.11M | 0 | 10.9M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 239K | 386K | 398K | 409K | 9.1M | 10.31M | 14.08M | 17.74M | 19.7M |
Total Liabilities | 29.57M | 35.81M | 41.13M | 48.39M | 47.95M | 81.59M | 114.81M | 160.96M | 188.85M | 176.89M |
Total Debt | 0 | 0 | 3.46M | 2.55M | 526K | 1.14M | 151K | 6.94M | 6.11M | 9.64M |
Net Debt | -104.03M | -206.76M | -27.81M | -73.64M | -77.09M | -65.19M | -135.4M | -120.73M | -114.39M | -99.1M |
Debt / Equity | - | - | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | 0.02x |
Debt / EBITDA | - | - | 0.03x | 0.02x | 0.00x | 0.01x | 0.00x | 0.05x | 0.13x | -1.42x |
Net Debt / EBITDA | -1.96x | -2.30x | -0.24x | -0.56x | -0.60x | -0.57x | -1.25x | -0.87x | -2.45x | 14.59x |
Interest Coverage | 1078.67x | - | - | - | - | - | - | - | - | - |
Total Equity | 190.97M▲ 0% | 275.88M▲ 44.5% | 371.18M▲ 34.5% | 523.34M▲ 41.0% | 375.81M▼ 28.2% | 501.84M▲ 33.5% | 506.7M▲ 1.0% | 679.59M▲ 34.1% | 647.8M▼ 4.7% | 637.99M▲ 0% |
Equity Growth % | 361.51% | 44.46% | 34.54% | 40.99% | -28.19% | 33.54% | 0.97% | 34.12% | -4.68% | -5.76% |
Book Value per Share | 1.53 | 2.18 | 3.03 | 4.21 | 2.98 | 4.33 | 4.53 | 5.99 | 5.40 | 6.11 |
Total Shareholders' Equity | 190.97M | 275.88M | 371.18M | 523.34M | 375.81M | 501.84M | 506.7M | 679.59M | 647.8M | 637.99M |
Common Stock | 115K | 117K | 120K | 122K | 127K | 131K | 133K | 136K | 140K | 141K |
Retained Earnings | -193.15M | -117.74M | -23.55M | 82.46M | 194.97M | 296.39M | 402.53M | 543.74M | 643.39M | 611.63M |
Treasury Stock | 0 | -23.66M | -62.7M | -75.8M | -410.41M | -456.15M | -635.08M | -696.17M | 0 | 0 |
Accumulated OCI | -75K | -70K | 261K | 415K | -227K | -869K | 609K | -217K | 2.26M | 918K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CORT Cash Flow Statement
Corcept Therapeutics Incorporated (CORT) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 60.94M | 115.67M | 136.12M | 151.97M | 167.89M | 120.32M | 127.04M | 198.07M | 142M | 120.1M |
Operating CF Margin % | 38.28% | 46.04% | 44.41% | 42.94% | 45.87% | 29.94% | 26.34% | 29.34% | 18.65% | - |
Operating CF Growth % | 231.33% | 89.82% | 17.68% | 11.65% | 10.48% | -28.33% | 5.58% | 55.91% | -28.31% | -481.74% |
Net Income | 129.12M | 75.41M | 94.18M | 106.01M | 112.51M | 101.42M | 106.14M | 141.21M | 98.17M | 47.9M |
Depreciation & Amortization | 106K | 236K | 2.17M | 2.24M | 3.07M | 3.45M | 2.36M | 1.34M | 1.89M | 2.03M |
Stock-Based Compensation | 13.36M | 23.75M | 29.31M | 33.54M | 42.93M | 42.44M | 48.94M | 61.35M | 84.5M | -21.67M |
Deferred Taxes | -76.7M | 14.07M | 16.88M | 14.09M | 4.35M | -33.91M | -29.49M | -40.19M | 0 | -21.76M |
Other Non-Cash Items | 763K | -1.72M | -1.74M | 1.45M | 5.09M | 1.38M | -9.13M | -10.94M | -15M | 18.3M |
Working Capital Changes | -5.71M | 3.93M | -4.69M | -5.36M | -57K | 5.54M | 8.22M | 45.3M | -27.57M | 22.27M |
Change in Receivables | -5.44M | -2.29M | -2.34M | -6.27M | -1.43M | -17.43M | -10.07M | 1.15M | -5.81M | 22.75M |
Change in Inventory | -2.26M | -7.78M | -1.04M | -3.51M | 3.44M | 1.2M | 1.26M | 305K | -7.48M | -11.36M |
Change in Payables | 6.29M | -389K | -735K | 3.16M | -3.6M | 4.76M | 5.78M | -2.25M | 25.07M | 4.5M |
Cash from Investing | -73.46M | -90.77M | -117.83M | -119.26M | 136.13M | -114.33M | 90.91M | -177.6M | 69.76M | 77.47M |
Capital Expenditures | -419K | -298K | -1.09M | -1.24M | -469K | -413K | -139K | -2.17M | -211K | -308K |
CapEx % of Revenue | 0.26% | 0.12% | 0.36% | 0.35% | 0.13% | 0.1% | 0.03% | 0.32% | 0.03% | 0.04% |
Acquisitions | 0 | 0 | 116.74M | 118.03M | -136.59M | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -73.04M | -90.47M | -116.74M | -118.03M | 136.59M | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | -7.95M | -14.34M | -28.64M | 12.21M | -302.59M | -17.28M | -148.72M | -28.35M | -220.37M | -179.8M |
Debt Issued (Net) | -15.13M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | -23.66M | -30.98M | -9.95M | -295.99M | 0 | -145.43M | -6.05M | -245.86M | -164.56M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -23.66M | -30.98M | -9.95M | -295.99M | 0 | -145.43M | -15.66M | -245.86M | -187.78M |
Other Financing | 7.18M | 9.32M | 2.33M | 22.16M | -6.61M | -17.28M | -3.29M | -22.3M | 25.49M | -15.25M |
Net Change in Cash | -20.47M▲ 0% | 10.56M▲ 151.6% | -10.36M▼ 198.0% | 44.92M▲ 533.8% | 1.43M▼ 96.8% | -11.29M▼ 891.0% | 69.22M▲ 713.2% | -7.89M▼ 111.4% | -7.17M▲ 9.1% | 18.92M▲ 0% |
Free Cash Flow | 60.52M▲ 0% | 115.37M▲ 90.6% | 135.03M▲ 17.0% | 150.73M▲ 11.6% | 167.42M▲ 11.1% | 119.91M▼ 28.4% | 126.9M▲ 5.8% | 195.9M▲ 54.4% | 141.78M▼ 27.6% | 119.79M▲ 0% |
FCF Margin % | 38.01% | 45.92% | 44.06% | 42.59% | 45.75% | 29.84% | 26.31% | 29.02% | 18.62% | 15.58% |
FCF Growth % | 232.56% | 90.64% | 17.04% | 11.63% | 11.07% | -28.38% | 5.83% | 54.37% | -27.62% | -32.39% |
FCF per Share | 0.49 | 0.91 | 1.10 | 1.21 | 1.33 | 1.03 | 1.14 | 1.73 | 1.18 | 1.15 |
FCF Conversion (FCF/Net Income) | 0.47x | 1.53x | 1.45x | 1.43x | 1.49x | 1.19x | 1.20x | 1.42x | 1.42x | 2.50x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 377K | 1.35M | 6.74M | 10.86M | 9.1M | 39.75M | 47.6M | 60.27M | 0 | 0 |
CORT Key Ratios
Corcept Therapeutics Incorporated (CORT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 111.15% | 32.31% | 29.11% | 23.7% | 25.03% | 23.11% | 21.05% | 23.56% | 15.01% | 7.5% |
Return on Invested Capital (ROIC) | 86.69% | 86.02% | 40.58% | 24.25% | 24.95% | 22.97% | 19.92% | 22.09% | 6.15% | -1.16% |
Gross Margin | 97.77% | 97.92% | 98.2% | 98.42% | 98.56% | 98.66% | 98.66% | 98.39% | 98.3% | 98.25% |
Net Margin | 81.11% | 30.01% | 30.73% | 29.96% | 30.74% | 25.24% | 22% | 20.7% | 13.09% | 6.23% |
Debt / Equity | - | - | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | 0.02x |
Interest Coverage | 1078.67x | - | - | - | - | - | - | - | - | - |
FCF Conversion | 0.47x | 1.53x | 1.45x | 1.43x | 1.49x | 1.19x | 1.20x | 1.42x | 1.42x | 2.50x |
Revenue Growth | 95.77% | 57.82% | 21.99% | 15.46% | 3.42% | 9.8% | 20.04% | 39.94% | 12.79% | 12.2% |
Related:CORT Dividend History·CORT Revenue History·CORT Price History·CORT P/E History·CORT Financial Ratios·CORT Institutional Holders
CORT SEC Filings & Documents
Corcept Therapeutics Incorporated (CORT) SEC filings — annual & quarterly reports (10-K, 10-Q)
CORT Frequently Asked Questions
Corcept Therapeutics Incorporated (CORT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Corcept Therapeutics Incorporated (CORT) reported $769.1M in revenue for fiscal year 2025.
Corcept Therapeutics Incorporated (CORT) grew revenue by 12.8% over the past year. This is steady growth.
Yes, Corcept Therapeutics Incorporated (CORT) is profitable, generating $47.9M in net income for fiscal year 2025 (13.1% net margin).
Dividend & Returns
Corcept Therapeutics Incorporated (CORT) has a return on equity (ROE) of 15.0%. This is reasonable for most industries.
Corcept Therapeutics Incorporated (CORT) generated $119.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.